Literature DB >> 15835743

A new class of 5-fluoro-2'-deoxyuridine prodrugs conjugated with a tumor-homing cyclic peptide CNGRC by ester linkers: synthesis, reactivity, and tumor-cell-selective cytotoxicity.

Zhouen Zhang1, Hiroshi Hatta, Kazuhito Tanabe, Sei-ichi Nishimoto.   

Abstract

PURPOSE: Tumor-targeting prodrugs of 5-fluoro-2'-deoxyuridine (5-FdUrd), which are chemical conjugations of 5-FdUrd with a tumor-homing cyclic peptide CNGRC by succinate and glutarate linkers, were synthesized to investigate the structural effects of linkers on the hydrolytic release of 5-FdUrd and the tumor-cell-selective cytotoxicity.
METHODS: A solid phase synthesis method was used to produce 5-FdUrd prodrugs. The kinetics and efficiency of hydrolytic 5-FdUrd release from the prodrugs were investigated in phosphate buffer (PB), fetal bovine serum (FBS), HT-1080 cell lysate, MDA-MB-231 cell lysate, and MEM containing 10% FBS. The tumor-cell-selective cytotoxicity of prodrugs was evaluated by an MTT method.
RESULTS: Two tumor-targeting prodrugs CNF1 and CNF2 bearing 5-FdUrd conjugated with a common cyclic peptide CNGRC by succinate and glutarate linkers, respectively, and their control compounds CN1 and CN2 without 5-FdUrd moiety were synthesized and identified. CNF1 underwent hydrolysis to release 5-FdUrd more rapidly and efficiently than CNF2. Both prodrugs were of lower cytotoxicity compared to 5-FdUrd, showing more selective cytotoxicity toward APN/CD13 positive cells (HT-1080) than toward APN/CD13 negative cells (HT-29, MDA-MB-231).
CONCLUSIONS: A new class of tumor-targeting 5-FdUrd prodrugs CNF1 and CNF2 were successfully synthesized. These prodrugs targeted a tumor marker APN/CD13 to cause tumor-cell-selective cyctotoxicity due to 5-FdUrd release, the rate of which could be controlled by the structure of ester linker.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15835743     DOI: 10.1007/s11095-004-1875-x

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  36 in total

Review 1.  Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.

Authors:  D C Drummond; O Meyer; K Hong; D B Kirpotin; D Papahadjopoulos
Journal:  Pharmacol Rev       Date:  1999-12       Impact factor: 25.468

2.  Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes.

Authors:  Gerben A Koning; Jan A A M Kamps; Gerrit L Scherphof
Journal:  Cancer Detect Prev       Date:  2002

3.  A photoactivated prodrug.

Authors:  Y Wei; Y Yan; D Pei; B Gong
Journal:  Bioorg Med Chem Lett       Date:  1998-09-22       Impact factor: 2.823

Review 4.  The pharmacology of the fluoropyrimidines.

Authors:  C E Myers
Journal:  Pharmacol Rev       Date:  1981-03       Impact factor: 25.468

5.  Synthesis and evaluation of bifunctional anti-HIV agents based on specific CXCR4 antagonists-AZT conjugation.

Authors:  H Tamamura; A Omagari; K Hiramatsu; T Kanamoto; K Gotoh; K Kanbara; N Yamamoto; H Nakashima; A Otaka; N Fujii
Journal:  Bioorg Med Chem       Date:  2001-08       Impact factor: 3.641

6.  Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells.

Authors:  Flavio Curnis; Gianluigi Arrigoni; Angelina Sacchi; Lucia Fischetti; Wadih Arap; Renata Pasqualini; Angelo Corti
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

Review 7.  Nanoparticles in cancer therapy and diagnosis.

Authors:  Irène Brigger; Catherine Dubernet; Patrick Couvreur
Journal:  Adv Drug Deliv Rev       Date:  2002-09-13       Impact factor: 15.470

8.  Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.

Authors:  Fabio Pastorino; Chiara Brignole; Danilo Marimpietri; Michele Cilli; Claudio Gambini; Domenico Ribatti; Renato Longhi; Theresa M Allen; Angelo Corti; Mirco Ponzoni
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

9.  One-electron reduction characteristics of N(3)-substituted 5-fluorodeoxyuridines synthesized as radiation-activated prodrugs.

Authors:  Kazuhito Tanabe; Youhei Mimasu; Akira Eto; Yukihiro Tachi; Shingo Sakakibara; Mayuko Mori; Hiroshi Hatta; Sei-ichi Nishimoto
Journal:  Bioorg Med Chem       Date:  2003-10-15       Impact factor: 3.641

Review 10.  Molecular targeting of angiogenesis.

Authors:  Patrizia Alessi; Christina Ebbinghaus; Dario Neri
Journal:  Biochim Biophys Acta       Date:  2004-03-04
View more
  5 in total

1.  Synthesis and evaluation of novel Tc-99m labeled probestin conjugates for imaging APN/CD13 expression in vivo.

Authors:  Gopal Pathuri; Andria F Hedrick; Bryan C Disch; John T Doan; Michael A Ihnat; Vibhudutta Awasthi; Hariprasad Gali
Journal:  Bioconjug Chem       Date:  2011-12-20       Impact factor: 4.774

2.  Peptide targeting of platinum anti-cancer drugs.

Authors:  Margaret W Ndinguri; Rajasree Solipuram; Robert P Gambrell; Sita Aggarwal; Robert P Hammer
Journal:  Bioconjug Chem       Date:  2009-09-23       Impact factor: 4.774

3.  Design of enzymatically cleavable prodrugs of a potent platinum-containing anticancer agent.

Authors:  Song Ding; Amanda J Pickard; Gregory L Kucera; Ulrich Bierbach
Journal:  Chemistry       Date:  2014-10-10       Impact factor: 5.236

Review 4.  Aminopeptidase N (CD13) as a target for cancer chemotherapy.

Authors:  Malin Wickström; Rolf Larsson; Peter Nygren; Joachim Gullbo
Journal:  Cancer Sci       Date:  2011-01-30       Impact factor: 6.716

5.  Antitumor activity of antimicrobial peptides containing CisoDGRC in CD13 negative breast cancer cells.

Authors:  Lei Hou; Xinhan Zhao; Pei Wang; Qian Ning; Min Meng; Caigang Liu
Journal:  PLoS One       Date:  2013-01-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.